Thomas K. Equels, CEO and President of AIM ImmunoTech Inc., filed a Form 4 on November 17, 2026, disclosing a purchase of 38,000 shares of common stock on November 16, 2026.

Key Highlights

  • Reporting person: Thomas K. Equels, identified as Director, CEO, and President of AIM ImmunoTech Inc.
  • Transaction: Acquisition (transaction code P) of 38,000 shares of common stock on November 16, 2026.
  • Price per share: $0.135, as reported in the filing.
  • Post-transaction ownership: Equels directly beneficially owns 366,095 shares of common stock following the reported transaction.
  • No derivative securities: Table II of the filing contains no reported derivative securities transactions.

Equels Purchase Details and Resulting Ownership in AIM ImmunoTech

According to the filing, Thomas K. Equels, who serves as both a Director and as CEO and President of AIM ImmunoTech Inc. (NYSE American:AIM), acquired 38,000 shares of the company's common stock on November 16, 2026. The transaction was recorded under transaction code "P," indicating an open-market purchase. The reported price per share was $0.135.

Following the reported transaction, the filing states that Equels directly beneficially owns 366,095 shares of AIM ImmunoTech common stock. The ownership form is listed as direct. No indirect beneficial ownership was reported in connection with this transaction.

The Form 4 was filed on November 17, 2026, one day after the transaction date. The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1(c) plan, as the corresponding checkbox was not selected. Table II of the filing, covering derivative securities such as options or warrants, contains no reported transactions or holdings.

What Was Disclosed

AIM ImmunoTech's CEO and President, Thomas K. Equels, disclosed a direct open-market purchase of 38,000 shares of common stock at $0.135 per share on November 16, 2026, bringing his direct beneficial ownership to 366,095 shares.